LivaNova PLC $LIVN Shares Purchased by Quantinno Capital Management LP

Posted by Geri Gentry on Aug 9th, 2026

Quantinno Capital Management LP lifted its stake in LivaNova PLC (NASDAQ:LIVN – Free Report) by 263.8% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 55,562 shares of the company’s stock after acquiring an additional 40,289 shares during the period. Quantinno Capital Management LP owned 0.10% of LivaNova worth $3,532,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LivaNova by 4.0% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after acquiring an additional 1,360 shares during the period. Goldman Sachs Group Inc. lifted its position in LivaNova by 4.6% in the first quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock worth $32,012,000 after purchasing an additional 36,094 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in LivaNova by 10.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock worth $6,633,000 after purchasing an additional 15,405 shares during the period. Intech Investment Management LLC boosted its stake in LivaNova by 19.6% during the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after purchasing an additional 7,195 shares in the last quarter. Finally, Strs Ohio acquired a new position in shares of LivaNova during the 1st quarter valued at $130,000. 97.64% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other LivaNova news, Director Francesco Bianchi sold 1,800 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $75.75, for a total transaction of $136,350.00. Following the sale, the director directly owned 7,228 shares of the company’s stock, valued at $547,521. The trade was a 19.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.35% of the company’s stock.

LivaNova Stock Performance

Shares of LIVN opened at $76.22 on Friday. The company has a 50-day moving average of $79.64 and a two-hundred day moving average of $70.75. The stock has a market cap of $4.20 billion, a price-to-earnings ratio of 22.55 and a beta of 0.86. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.45 and a quick ratio of 1.11. LivaNova PLC has a one year low of $48.57 and a one year high of $85.76.

LivaNova (NASDAQ:LIVN – Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17. The business had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The firm’s revenue was up 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.05 earnings per share. LivaNova has set its FY 2026 guidance at 4.300-4.400 EPS. On average, equities research analysts expect that LivaNova PLC will post 3.75 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on LIVN. Needham & Company LLC boosted their price objective on LivaNova from $81.00 to $93.00 and gave the stock a “buy” rating in a research note on Wednesday. Robert W. Baird decreased their target price on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Mizuho lifted their target price on LivaNova from $90.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Zacks Research upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Stifel Nicolaus set a $85.00 price target on shares of LivaNova in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, LivaNova presently has an average rating of “Moderate Buy” and a consensus price target of $83.50.

Get Our Latest Research Report on LIVN

About LivaNova

(Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.